IRVINE, CA, Developer of the novel Hydrus Microstent device designed to lower eye pressure for glaucoma patients, announced today that it closed a $25 million Series C financing. more...
SAN FRANCISCO, CA, Leader in developing best-in-class therapies to address the unmet needs of migraine sufferers, today announced the closing of a $12 million Series A financing. more...